Regencell Bioscience Holdings Ltd annual report, Q4 FY2023

Business context and reporting period

Regencell Bioscience Holdings Limited filed its Form 20-F for the fiscal year ended June 30, 2023 (comparative year ended June 30, 2022); this is not a quarterly report for 2022 Q4. The Cayman Islands holding company operates primarily in Hong Kong and is an early-stage Traditional Chinese Medicine (TCM) research company focused on ADHD and autism spectrum disorder (ASD), with a separate COVID-treatment initiative. It has not generated product revenue. Financial statements are prepared under U.S. GAAP.

Financial results and liquidity

FY2023 research and development expense was $1.582 million, down 37%; general and administrative expense was $4.429 million, down 13%; and selling and marketing expense rose to $262,664 from $25,275. The company reported no income-tax provision. Revenue and profit margins are not applicable because there were no product sales.

At June 30, 2023, cash was $1.565 million and short-term investments were $10.0 million, for $11.621 million in total current assets. Total assets were $12.622 million; total liabilities were $632,320, including $463,669 of operating lease liabilities. No shareholder loans were outstanding. Management stated that cash and short-term investments should fund operations and obligations for at least 12 months from issuance of the audited statements, while noting that additional financing may be pursued. FY2023 investing cash flow was positive $58,978, and financing cash flow was positive $134,913.

Material changes versus the prior year

• Net loss narrowed by about 20%, mainly as operating expenses declined, including lower share-based compensation and professional fees. Other income increased, principally from interest income and government subsidies.
• Operating cash use remained substantial, while cash fell from $6.417 million to $1.565 million. The $10 million short-term investment remained on the balance sheet.
• Comprehensive loss included an $86,658 foreign-currency translation loss. Outstanding ordinary shares were 13,012,866 at both year-ends.

Outlook, risks and unusual items

The company reported completion of an uncontrolled second efficacy trial involving 28 patients. It described improvements on several parent-reported assessment scores, but the filing cautions that the study was small and uncontrolled and that results may be affected by caregiver reporting bias. The company also describes a plan to study approximately 100 patients for three to twelve months; the relationship between that planned work and the completed 28-patient trial should be clarified.

There is no quantified revenue or earnings guidance. Management expects no product revenue until commercialization, which depends on further research, safety and quality testing, Hong Kong manufacturer licensing and proprietary Chinese medicine registrations. The company plans to build production and sales capabilities and may pursue markets outside Hong Kong after establishing its initial market. The COVID-treatment initiative is being pursued through a 60%-owned joint venture, but its research and commercialization are expressly uncertain.

• Funding and execution: The company has a limited operating history, recurring losses and operating cash outflows; insufficient financing could delay or curtail its plans.
• Development and regulation: No candidates have marketing approval; the reported studies do not establish efficacy or safety, and the company has no product revenue or established distribution capability.
• Controls: Management concluded disclosure controls and internal control over financial reporting were ineffective at June 30, 2023, citing three material weaknesses: insufficient U.S. GAAP/SEC reporting expertise, no internal audit function and inadequate segregation of duties. Remediation efforts are ongoing.
• Concentration and governance: Founder and CEO Yat-Gai Au beneficially owns 81.2% of shares and controls the company. The strategic TCM practitioner is his father; the partnership provides exclusive formula rights and requires a donation of 3% of related net revenue upon commercialization.
• Other items: The company reported $0.923 million of share-based compensation, received government subsidies, and disclosed related-party spending for formula materials and research support. It reported no material pending legal proceedings and no material off-balance-sheet arrangements.

Important facts for investors to verify

1. Confirm the filing period: fiscal year ended June 30, 2023, rather than 2022 Q4.
2. Review the full trial protocols, patient-level results, adverse-event data and independent validation of the uncontrolled 28-patient findings; clarify the plan for the proposed 100-patient study.
3. Verify the maturity, availability and any restrictions on the $10 million short-term investment, and compare the 12-month liquidity assertion with the company’s continuing cash burn.
4. Track required Hong Kong manufacturing and product-registration approvals, and whether the company has secured production, sales and distribution capabilities.
5. Assess progress in remediating the three material weaknesses and the implications of concentrated ownership, related-party arrangements and outstanding options.